Company Profile
Genmab Stock Price, News & Catalysts
- Ticker:
- GMAB
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs
- Location:
- Copenhagen, Denmark
Stock performance
34.55 USD (-3.15%)
Close
Last updated: October 1, 2026
14.6B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, GMAB closed down 3.15% at $34.55. No new same-company headline was identified in the current news window.
Company overview
Antibody-Focused Biotechnology Company
Genmab is a global biotechnology company focused on creating differentiated antibody therapeutics for cancer and other serious diseases. It combines internal antibody discovery, proprietary engineering platforms, clinical development, commercialization, and a large network of pharmaceutical partnerships.
Proprietary Antibody Technologies
The company's technology base includes DuoBody bispecific antibodies, HexaBody antibodies with enhanced complement activation, DuoHexaBody constructs, and HexElect conditional effector-function technology. These platforms are designed to generate new mechanisms of action and can support both wholly owned programs and partnered medicines.
Commercial and Co-Commercialized Medicines
Genmab's direct commercial portfolio includes EPKINLY/TEPKINLY, an epcoritamab-based bispecific antibody for B-cell malignancies, and Tivdak for cervical cancer. The company shares economics and commercialization responsibilities with partners in selected markets while retaining the ability to build its own global oncology organization.
Royalty-Based Portfolio
Antibodies created with Genmab technology support a significant royalty business. Products contributing to this model include DARZALEX, Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY, and BIZENGRI, providing diversified exposure across oncology, immunology, and rare disease without requiring Genmab to fund every commercial infrastructure independently.
Late-Stage Oncology Pipeline
The late-stage proprietary pipeline is led by Rina-S, an antibody-drug conjugate targeting folate receptor alpha, and petosemtamab, an EGFRxLGR5 bispecific antibody added through the acquisition of Merus. Epcoritamab is also being developed across additional lymphoma settings and treatment lines, making lifecycle expansion an important part of the portfolio.
Future catalysts
- Phase 3 RAINFOL-02 data for Rina-S in platinum-resistant ovarian cancer during 2026.
- Phase 3 data from one or both LiGeR-HN studies of petosemtamab in head and neck squamous cell carcinoma during 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Genmab (GMAB)?
Genmab (GMAB) most recently closed at 34.55 USD, a -3.15% move versus the previous session.
What is the market cap of Genmab (GMAB)?
Genmab currently has a market capitalization of 14.6B USD on BioPharmSignal.
What does Genmab do?
Antibody-Focused Biotechnology Company Genmab is a global biotechnology company focused on creating differentiated antibody therapeutics for cancer and other serious diseases. It combines internal antibody discovery, proprietary engineering platforms, clinical development, commercialization, and a large network of pharmaceutical partnerships. Proprietary...
On which exchange is GMAB stock listed?
Genmab (GMAB) is associated with NASDAQ, Copenhagen, Denmark, Antibody Drugs.
What is RAINFOL-02?
Phase 3 RAINFOL-02 data for Rina-S in platinum-resistant ovarian cancer during 2026.
Which conditions is Genmab targeting with RAINFOL-02?
Genmab is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Genmab describe recent progress with RAINFOL-02?
Phase 3 RAINFOL-02 data for Rina-S in platinum-resistant ovarian cancer during 2026.
What is epcoritamab?
Commercial and Co-Commercialized Medicines Genmab's direct commercial portfolio includes EPKINLY/TEPKINLY, an epcoritamab-based bispecific antibody for B-cell malignancies, and Tivdak for cervical cancer.